News & Events about Acadia Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD Get Rating) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 8,700,000 shares, a decrease of 10.0% from the November 30th total of 9,670,000 shares. Based on an average ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinsons disease psychosis (PDP) treated with NUPLAZID (pimavanserin) compared to other atypical antipsychotics...
Business Wire
2 months ago
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD). On July 20, 2020, the Company announced that the FDA had accepted...
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD ACADIA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick &...
Ticker Report
4 months ago
Exchange Traded Concepts LLC boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD Get Rating) by 328.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,709 shares of the biopharmaceutical ...